Dichloroacetate (DCA) is an analog of the acetic acid that has been modified in the lab. It has various practical uses, but since it can inhibit the “pyruvate dehydrogenase kinase”-enzyme it has been studied as a potential drug for various diseases. More recently scientists have looked deeper into the possible anti-cancer characteristics of DCA and it is a drug that shows a lot of promise in the alternative oncology field.

It has been shown to change the metabolic matrix of cancer cells diverting it from anaerobic glycolysis to mitochondrial oxidative phosphorylation. DCA seems also to have the ability to disrupt cancer stem cells by downregulating the expression of specific markers. All in all, it shows promise in halting disease progress and inhibiting tumor growth with possibly long-term anti-tumor treatment.

DCA is recommended against a plethora of cancer types mainly due to the fact that it may be capable of fundamentally changing the metabolic matrix of cancerous cells as well as targeting specific markers on cancer stem cells, meaning it can potentially affect almost all types of cancer cells not only on “adult” cancer cells as well as on their stem cells.

We believe DCA to be a very effective therapy modality that, when combined with other treatment options, appears to show great responses in cancer and stem cancer cells, possibly preventing the tumors to relapse. It is also very well tolerated and patients experience normally little to no side effects. In our clinic, we only use intravenous formulations of DCA, because we believe that oral intake is not enough to reach a high enough level in the bloodstream for effective cancer therapy.